Palvella Therapeutics (PVLA) Operating Margin (2016 - 2024)
Historic Operating Margin for Palvella Therapeutics (PVLA) over the last 11 years, with Q4 2024 value amounting to 2412.15%.
- Palvella Therapeutics' Operating Margin rose 13816700.0% to 2412.15% in Q4 2024 from the same period last year, while for Dec 2024 it was 11011.72%, marking a year-over-year increase of 110393800.0%. This contributed to the annual value of 3277.91% for FY2024, which is 33056300.0% up from last year.
- As of Q4 2024, Palvella Therapeutics' Operating Margin stood at 2412.15%, which was up 13816700.0% from 3318.87% recorded in Q1 2024.
- Over the past 5 years, Palvella Therapeutics' Operating Margin peaked at 2412.15% during Q4 2024, and registered a low of 3318.87% during Q1 2024.
- For the 5-year period, Palvella Therapeutics' Operating Margin averaged around 213.55%, with its median value being 163.66% (2021).
- Data for Palvella Therapeutics' Operating Margin shows a peak YoY increase of 13816700bps (in 2024) and a maximum YoY decrease of -25471800bps (in 2024) over the last 5 years.
- Over the past 5 years, Palvella Therapeutics' Operating Margin (Quarter) stood at 661.21% in 2020, then soared by 80bps to 130.27% in 2021, then plummeted by -51bps to 197.04% in 2022, then surged by 623bps to 1030.48% in 2023, then surged by 134bps to 2412.15% in 2024.
- Its Operating Margin stands at 2412.15% for Q4 2024, versus 3318.87% for Q1 2024 and 1030.48% for Q4 2023.